Status:

COMPLETED

Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

Lead Sponsor:

AstraZeneca

Conditions:

Diabetes Mellitus

Eligibility:

All Genders

18-130 years

Phase:

PHASE3

Brief Summary

Study D5553C00002 is a multicenter, randomized, double-blind, placebo-controlled, parallel group, Phase 3 study to compare the safety and efficacy of exenatide once weekly (EQW) added to titrated basa...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Has a diagnosis of Type 2 Diabetes Mellitus (T2DM)
  • Has HbA1c of 7.5% to 12.0%, inclusive, at Visit 1 (Screening).
  • Has fasting plasma glucose (FPG) concentration \<280 mg/dL (15.6 mmol/L) at Visit 1 (Screening)
  • Treated with basal insulin glargine at a dose of ≥20 units/day once daily for at least 6 weeks prior to Screening, in combination with diet and exercise alone or in combination with:
  • a stable dose of metformin (≥1500 mg/day) for at least 8 weeks prior to Visit 1
  • a stable dose of metformin (≥1500 mg/day) for at least 8 weeks prior to Visit 1 (Screening) and a stable dose of sulfonylurea for at least 8 weeks prior to the Screening visit
  • Exclusion criteria:
  • Serum calcitonin concentration ≥40 pg/mL (≥40 ng/L) at Visit 1 (Screening)
  • History of, or currently have, acute or chronic pancreatitis, or have triglyceride concentrations ≥500 mg/dL (≥5.65 mmol/L) at Visit 1
  • Positive serological test for hepatitis B or hepatitis C

Exclusion

    Key Trial Info

    Start Date :

    September 6 2014

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    August 29 2016

    Estimated Enrollment :

    464 Patients enrolled

    Trial Details

    Trial ID

    NCT02229383

    Start Date

    September 6 2014

    End Date

    August 29 2016

    Last Update

    January 8 2019

    Active Locations (123)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 31 (123 locations)

    1

    Research Site

    Birmingham, Alabama, United States, 35235

    2

    Research Site

    Huntsville, Alabama, United States, 35801

    3

    Research Site

    Muscle Shoals, Alabama, United States, 35662

    4

    Research Site

    Tempe, Arizona, United States, 85283